For example, the sensitivity is limited by the expression of the wild type gene in the tissue of interest, leading to an estimated subset of only 13–46% of AML patients with WT1 expression high enough to serve as MRD marker [36]. This evidence concerns the gene WT1 and acute myeloid leukemia.